About Novacyl. - CPHI Online
NOVACYL is a worldwide leader in Rhodine (Acetylsalicylic acid), Salicylic Acid and dérivatives, as well as a major player in Paracetamol, with world-leading technology, supported by a recognized regulatory expertise, with a unique vertical integration on key raw materials (Phenol and Para Aminophenol).
Manufacturer of pharmaceutical & specialty ingredients - Seqens
SEQENS is a world leader in the development and production of active ingredients, pharmaceutical intermediates, specialty ingredients and cosmetics and personal care products, with 16 production sites, 9 R&D centers and 3,300 employees in 9 …
Novacyl Company Profile 2024: Valuation, Investors ...
Powered by LCD (Leveraged Commentary & Data), the most comprehensive provider of credit market news, research, data, and indexes covering US and European leveraged loans, high-yield bonds, private debt, and CLOs. Find comprehensive private and public capital markets research—including asset classes, industries, and companies, all in one place.
Novacyl Asia Pacific Ltd - CPHI Online
Novacyl is a worldwide leader on acetylsalicylic acid and intermediates (Salicylic Acid, Esters) and key player in Paracetamol. Novacyl's world-leading technology, supported by a unique regulatory expertise, is unanimously recognized amongst the largest pharmaceutical companies.
Novacyl SAS - Company Profile and News - Bloomberg Markets
Novacyl develops and manufactures pharmaceutical ingredients. The Company offers acetylsalicylic acid, paracetamol, salicylic acid, and aminophenol. Novacyl serves pharmaceutical, health care,...
Novacyl - Perfumer & Flavorist
Novacy Inc, is a leading manufacturer of high quality pharmaceutical products dedicated to providing active ingredients and intermediates for the flavor & fragrance, personal care, cosmetics, pharmaceutical and consumer health markets.
Novacap completes the acquisition of Rhodia’s analgesic ...
2011年11月2日 · Novacap has completed the carve-out of Rhodia’s salicylic and acetaminophen businesses, with the support of its majority shareholder AXA Private Equity. These activities will become Novacyl, a newly created company within Novacap.